FY2018 Earnings Estimate for Shire PLC Issued By Leerink Swann (SHPG)
Shire PLC (NASDAQ:SHPG) – Equities researchers at Leerink Swann upped their FY2018 EPS estimates for Shire PLC in a research note issued to investors on Monday. Leerink Swann analyst J. Gerberry now forecasts that the brokerage will earn $17.51 per share for the year, up from their prior estimate of $17.41. Leerink Swann currently has a “Buy” rating and a $198.00 target price on the stock. Leerink Swann also issued estimates for Shire PLC’s FY2019 earnings at $19.92 EPS and FY2020 earnings at $21.67 EPS.
Several other brokerages have also recently issued reports on SHPG. Jefferies Group set a $248.00 price objective on Shire PLC and gave the stock a “buy” rating in a report on Friday, November 11th. Zacks Investment Research raised Shire PLC from a “sell” rating to a “hold” rating in a report on Thursday, August 4th. Citigroup Inc. reaffirmed a “buy” rating on shares of Shire PLC in a report on Tuesday, September 27th. BNP Paribas reaffirmed a “buy” rating on shares of Shire PLC in a report on Sunday, October 23rd. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of Shire PLC in a report on Monday, August 1st. Four research analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the company. Shire PLC currently has an average rating of “Buy” and a consensus price target of $222.06.
Shire PLC (NASDAQ:SHPG) traded down 0.67% during trading on Wednesday, hitting $179.82. The stock had a trading volume of 537,128 shares. Shire PLC has a one year low of $147.60 and a one year high of $219.52. The stock’s 50-day moving average is $184.66 and its 200 day moving average is $187.67. The firm has a market cap of $53.56 billion, a price-to-earnings ratio of 37.37 and a beta of 1.46.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $3.17 earnings per share for the quarter, missing analysts’ consensus estimates of $3.21 by $0.04. The business had revenue of $3.45 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Shire PLC had a return on equity of 14.81% and a net margin of 1.62%. The business’s revenue for the quarter was up 108.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.24 earnings per share.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC boosted its position in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares during the period. Canal Insurance CO acquired a new position in Shire PLC during the second quarter valued at approximately $102,000. FTB Advisors Inc. boosted its position in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the period. Duncker Streett & Co. Inc. acquired a new position in Shire PLC during the second quarter valued at approximately $111,000. Finally, Ropes Wealth Advisors LLC acquired a new position in Shire PLC during the second quarter valued at approximately $114,000. Institutional investors and hedge funds own 24.62% of the company’s stock.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.